Hitt og þetta 28. ágúst 2006

Gambro and DaVita reach agreement on Amended Alliance and Product Supply Agreement

Gambro AB, Gambro Renal Products, Inc. and DaVita Inc. have agreed to an amended and restated Alliance and Product Supply Agreement. This amendment effectively revokes the termination notice which was provided by DaVita in May primarily as a result of Gambro Renal Products' inability to supply monitors due to the current Import Alert declared by the FDA.

"We are pleased to have reached this agreement with DaVita," says Jon Risfelt, President Gambro Renal Products. "DaVita is a very important customer for us and now we can focus on meeting its long-term needs and the needs of the thousands of patients DaVita serves."

The Supply Agreement was originally entered into as part of the agreement to divest Gambro's U.S. dialysis clinics to DaVita in October 2005. Under the amendment, Gambro will continue to be the preferred supplier of renal products to DaVita.

For further information please contact: Paula Treutiger, Vice President, Corporate Communications, tel. +46-8-613 65 99, +46-73-366 65 99 Pia Irell, Vice President, Communications, Gambro Renal Products tel. +46-8-613 65 91, +46-70 513 65 91

Gambro is a global medical technology company with related services and has leading positions in renal care - services and products - and blood component technology. Gambro Renal Products develops and supplies hemodialysis, peritoneal dialysis, and acute renal and liver dialysis products, therapies and services. Gambro Healthcare is a provider of end-stage renal disease treatment and patient care. Gambro BCT develops and provides blood collection, apheresis and cell therapy products and services.